Breaking News Instant updates and real-time market news.

NBIX

Neurocrine

$45.67

1.37 (3.09%)

04:55
10/21/16
10/21
04:55
10/21/16
04:55

Neurocrine management to meet with JPMorgan

Meetings to be held in Chicago on October 20 and on Denver on October 21 hosted by JPMorgan.

  • 21

    Oct

  • 06

    Nov

  • 29

    Nov

  • 14

    Dec

NBIX Neurocrine
$45.67

1.37 (3.09%)

10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
10/12/16
LEER
10/12/16
NO CHANGE
Target $70
LEER
Outperform
Neurocrine recent selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.
10/13/16
BMOC
10/13/16
NO CHANGE
BMOC
Neurocrine recent weakness unwarranted, says BMO Capital
BMO Capital analyst M. Ian Somaiya says that Neurocrine (NBIX) has been weak recently in the wake of Myovant's S-1 filing. According to the analyst, investors view Myovant's relugolix as a more convenient alternative to Neurocrine's elagolix. However, the analyst thinks that relugolix's longer half-life "could complicate add-back therapy," while the wording of the questionnaire for relugolix's Phase 3 trial increases endometriosis clinical development risk. Additionally, the analyst says that Neurocrine's elagolix has a two to three year lead time over relugolix, setting the stage for both drugs to do well. He keeps a $66 price target and Outperform rating on Neurocrine.
10/18/16
NEED
10/18/16
INITIATION
Target $62
NEED
Buy
Neurocrine initiated with a Buy at Needham
Needham analyst Alan Carr initiated Neurocrine with a Buy and a $62 price target.

TODAY'S FREE FLY STORIES

ORBK

Orbotech

$51.47

0.38 (0.74%)

06:05
01/17/18
01/17
06:05
01/17/18
06:05
Earnings
Orbotech sees FY18 revenue up 12%-14% »

Sees 12-14% revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORBK

Orbotech

$51.47

0.38 (0.74%)

06:04
01/17/18
01/17
06:04
01/17/18
06:04
Earnings
Breaking Earnings news story on Orbotech »

Orbotech sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$4.11

-0.14 (-3.29%)

06:03
01/17/18
01/17
06:03
01/17/18
06:03
Hot Stocks
Amarin initiates clinical development of Vascepa in China »

Amarin's partner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUVA

NuVasive

$51.99

-1.34 (-2.51%)

06:03
01/17/18
01/17
06:03
01/17/18
06:03
Downgrade
NuVasive rating change  »

Wells Fargo sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.55 (-2.93%)

06:03
01/17/18
01/17
06:03
01/17/18
06:03
Hot Stocks
GE: Peter Stracar to succeed Mark Hutchinson as President and CEO of GE Europe »

GE announces the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

KL

Kirkland Lake Gold

$16.74

0.62 (3.85%)

06:03
01/17/18
01/17
06:03
01/17/18
06:03
Hot Stocks
Kirkland Lake Gold sees FY18 production growth to over 620,000 ounces »

Highlights of 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORBK

Orbotech

$51.47

0.38 (0.74%)

06:02
01/17/18
01/17
06:02
01/17/18
06:02
Earnings
Orbotech reports preliminary Q4 revenue of about $256M, consensus $250.16M »

Gross margin is expected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$24.66

-0.75 (-2.95%)

06:01
01/17/18
01/17
06:01
01/17/18
06:01
Periodicals
Twitter sued by TWiT for breach of contract, infringement, TechCrunch reports »

Twitter is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

SLGN

Silgan Holdings

$29.29

-0.23 (-0.78%)

, CCK

Crown Holdings

$57.79

-0.31 (-0.53%)

05:58
01/17/18
01/17
05:58
01/17/18
05:58
Downgrade
Silgan Holdings, Crown Holdings, Berry Global, Ball Corp. rating change  »

Silgan Holdings…

SLGN

Silgan Holdings

$29.29

-0.23 (-0.78%)

CCK

Crown Holdings

$57.79

-0.31 (-0.53%)

BERY

Berry Global

$59.13

-1.1 (-1.83%)

BLL

Ball Corp.

$38.39

0.49 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 07

    Feb

  • 08

    Feb

ABB

ABB

$28.07

-0.02 (-0.07%)

05:55
01/17/18
01/17
05:55
01/17/18
05:55
Downgrade
ABB rating change  »

ABB downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

IFF

International Flavors

$152.54

-1.16 (-0.75%)

05:54
01/17/18
01/17
05:54
01/17/18
05:54
Upgrade
International Flavors rating change  »

International Flavors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADNT

Adient

$81.91

-0.51 (-0.62%)

05:54
01/17/18
01/17
05:54
01/17/18
05:54
Downgrade
Adient rating change  »

Adient downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

AEP

American Electric

$67.50

0.04 (0.06%)

05:53
01/17/18
01/17
05:53
01/17/18
05:53
Upgrade
American Electric rating change  »

American Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$116.64

-1.53 (-1.29%)

05:53
01/17/18
01/17
05:53
01/17/18
05:53
Downgrade
PPG rating change  »

PPG downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

NBR

Nabors Industries

$8.23

0.04 (0.49%)

05:52
01/17/18
01/17
05:52
01/17/18
05:52
Downgrade
Nabors Industries rating change  »

Nabors Industries resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

ETH

Ethan Allen

$28.15

-0.5 (-1.75%)

05:52
01/17/18
01/17
05:52
01/17/18
05:52
Downgrade
Ethan Allen rating change  »

Ethan Allen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

QTS

QTS Realty Trust

$52.47

0.82 (1.59%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Downgrade
QTS Realty Trust rating change  »

QTS Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQ

La Quinta

$18.44

-0.03 (-0.16%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Upgrade
La Quinta rating change  »

La Quinta upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASND

Ascendis Pharma

$47.60

1.02 (2.19%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Recommendations
Ascendis Pharma analyst commentary  »

Ascendis Pharma price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLX

Shell Midstream

$30.74

0.21 (0.69%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Downgrade
Shell Midstream rating change  »

Shell Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

ENR

Energizer

$59.11

7.49 (14.51%)

05:47
01/17/18
01/17
05:47
01/17/18
05:47
Downgrade
Energizer rating change  »

Energizer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 31

    Jan

ABB

ABB

$28.07

-0.02 (-0.07%)

05:46
01/17/18
01/17
05:46
01/17/18
05:46
Upgrade
ABB rating change  »

ABB upgraded to Hold from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CELG

Celgene

$104.82

-1.18 (-1.11%)

, JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

05:45
01/17/18
01/17
05:45
01/17/18
05:45
Recommendations
Celgene, Juno Therapeutics analyst commentary  »

Jefferies believes $8B…

CELG

Celgene

$104.82

-1.18 (-1.11%)

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

DF

Dean Foods

$11.28

0.01 (0.09%)

05:45
01/17/18
01/17
05:45
01/17/18
05:45
Upgrade
Dean Foods rating change  »

Dean Foods upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$176.19

-0.9 (-0.51%)

05:44
01/17/18
01/17
05:44
01/17/18
05:44
Downgrade
Apple rating change  »

Apple downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.